| HOME >> BIOLOGY >> TECHNOLOGY |
At June 30, 2007 net deferred tax liabilities of $1,163.9 million were recognized (December 31, 2006: $27.2 million). The increase in net deferred tax liabilities at June 30, 2007 as compared to December 31, 2006 has primarily resulted from the recognition of net deferred tax liabilities totaling $1,150.7 million following the acquisition of New River.
Principal Differences: IFRS and US GAAP Net Income for the six months to June 30, 2007 and 2006.
The principal differences between IFRS net income and the US GAAP net loss for the six months ending June 30, 2007 resulted from the acquisition of New River. The primary differences arising from the New River acquisition relate to:
(a) In-process research and development ("IPR&D")
IPR&D totaling $1,943.3 million in respect of VYVANSE indicated for non-pediatric patients in the US and VYVANSE in the rest of the world ("RoW") has been capitalized as an intangible asset under IFRS. As required under US GAAP the value ascribed to these IPR&D assets ($1,896.0 million) has been charged to research and development expense as of the acquisition date.
(b) Effective settlement of pre-existing relationship with New River
Prior to the acquisition of New River Shire had entered into a collaboration agreement with New River which governed the development, manufacture and commercialization of VYVANSE in the US and RoW territories. As a result of the existence of this collaboration agreement, Shire's acquisition of New River has been accounted for as a multiple element transaction under both IFRS and US GAAP, with one element being the business combination and the other element being the effective settlement of the pre-existing relationship.
Under both US GAAP and IFRS the pre-existing relationship was
effectively settled at no incremental cost to Shire. No charge has been
re
'/>"/>
| SOURCE Shire plc Copyright©2007 PR Newswire. All rights reserved |